Efficacy matters [Carta]: broadening complement inhibition in COVID-19 (2021)
Source: The Lancet Rheumatology. Unidade: FMRP
Subjects: ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, COVID-19, NEUTRÓFILOS, COAGULAÇÃO
ABNT
MASTELLOS, Dimitrios C. et al. Efficacy matters [Carta]: broadening complement inhibition in COVID-19. The Lancet Rheumatology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/S2665-9913(20)30423-9. Acesso em: 17 nov. 2024. , 2021APA
Mastellos, D. C., Skendros, P., Calado, R. T., Risitano, A. M., & Lambris, J. D. (2021). Efficacy matters [Carta]: broadening complement inhibition in COVID-19. The Lancet Rheumatology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/S2665-9913(20)30423-9NLM
Mastellos DC, Skendros P, Calado RT, Risitano AM, Lambris JD. Efficacy matters [Carta]: broadening complement inhibition in COVID-19 [Internet]. The Lancet Rheumatology. 2021 ; 3( 2): e95.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/S2665-9913(20)30423-9Vancouver
Mastellos DC, Skendros P, Calado RT, Risitano AM, Lambris JD. Efficacy matters [Carta]: broadening complement inhibition in COVID-19 [Internet]. The Lancet Rheumatology. 2021 ; 3( 2): e95.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/S2665-9913(20)30423-9